Though this suggestion provides one possible mechanism through which an Aurora A kinase inhibitor and MEK inhibitor may act synergistically in select colorectal cancer models, there is also data indicating that MEK inhibition induces degradation of c-Myc (Duncan et al., 2012). Here, MAP2K7 is linked to colorectal cancer.